Sugi Predict

Sugi Predict / Compounds / SCHEMBL41220

SCHEMBL41220

SCHEMBL41220

O=C(CBr)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A1 P22736 1/20 0.70
▸ NR4A2 P43354 1/20 0.70
▸ NR4A3 Q92570 1/20 0.70
▸ MAOB P27338 1/20 0.66
▸ PARP10 Q53GL7 1/20 0.66
▸ SRD5A2 P31213 1/20 0.64
▸ EGFR P00533 4/20 0.62
▸ PLA2G4B P0C869 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ PTPN1 P18031 3/20 0.58
▸ GSK3B P49841 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ PTGS1 P23219 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7376701 0.95 PTPN1 (0.65) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL4456868 0.95 NR4A1 (0.64) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL27517502 0.87 EGFR (0.68) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL2451027 0.85 MEN1 (0.71) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL2006466 0.85 MAPK1 (0.56) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL4220632 0.85 NR4A1 (0.72) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL1960673 0.85 NR4A1 (0.72) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL23407659 0.84 NR4A2 (0.69) NR4A2MAOBPARP10RAB9APTPN1
SCHEMBL7500366 0.84 NR4A2 (0.69) NR4A2MAOBPARP10ALDH1A1MAPT
SCHEMBL8557179 0.84 GSK3B (0.75) MAOBPARP10PLA2G4BALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106810487-A A kind of high efficiency preparation method of Bazedoxifene 四川科伦药物研究院有限公司 2017-06-09 — — CN claimed
CN-103739540-A Method for preparing bazedoxifene acetate intermediate CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD 2014-04-23 — — CN claimed
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 — — US disclosed
US-20250145598-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF UNIV CALIFORNIA (US) 2025-05-08 — — US disclosed
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP disclosed
US-12145909-B2 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B NOVARTIS AG (CH) 2024-11-19 — — US disclosed
EP-4387617-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2024-06-26 — — EP disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 — — US disclosed
EP-4282412-A2 N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B Novartis AG (CH) 2023-11-29 — — EP disclosed
US-11793774-B2 Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia ATROGI AB (SE) 2023-10-24 — — US disclosed
US-11793774-B2 Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia ATROGI AB (SE) 2023-10-24 — — US disclosed
EP-0117647-A1 Improvements in or relating to phenethanolamines ELI LILLY AND COMPANY (US) 1984-09-05 — — EP disclosed
US-4378361-A BRONCHODILATOR, MUSCLE RELAXANTS, ANTIALLERGENS, AND HYPOTENSIVE AGENT BOEHRINGER INGELHEIM KG (DE) 1983-03-29 — — US disclosed
EP-0008653-B1 N-substituted benzimidazoles, processes for their preparation and medicines containing them C.H. BOEHRINGER SOHN (DE) 1982-06-16 — — EP disclosed
EP-0008653-A1 N-substituted benzimidazoles, processes for their preparation and medicines containing them C.H. BOEHRINGER SOHN (DE) 1980-03-19 — — EP disclosed
US-4146638-A CARDIOTONIC, VASODILATION, HYPOTENSIVE, ANTIARRYTHMIA AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1979-03-27 — — US disclosed
US-4137328-A CONGESTIVE HEART FAILURE PFIZER INC. (US) 1979-01-30 — — US disclosed
US-3976694-A BETA-ADRENERGIC STIMULANT, BRONCHODILATOR SMITHKLINE CORPORATION (US) 1976-08-24 — — US disclosed
US-3966814-A PERIPHERAL VASODILATORS, ANTIHISTAMINES, SPASMOLYTICS BOEHRINGER INGELHEIM GMBH (DT) 1976-06-29 — — US disclosed
US-3961076-A BRONCHODILATORS SMITHKLINE CORPORATION (US) 1976-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145598-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF ASAH2, ASAH1, ACER2 NR4A1 4655/4885NR4A2 4304/4885NR4A3 4216/4885
US-12145909-B2 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B GRIN2A, GRIN2C, GRIN3A NR4A1 248/4885NR4A2 252/4885NR4A3 322/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG NR4A1 3370/4885NR4A2 2868/4885NR4A3 2664/4885
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 NR4A1 161/4885NR4A2 80/4885NR4A3 69/4885
US-11793774-B2 Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia GPR119, SLC5A1, SLC5A2 NR4A1 411/4885NR4A2 1088/4885NR4A3 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.